Drug Trial Radar · NCT04688736
Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
6,642
Planned (sponsor's estimate)
Start
Jan 1, 2021
Primary completion
Dec 31, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, randomized, double-blind controlled trial to evaluate the efficacy of placebo versus chlorpheniramine for the prevention of allergic transfusion reactions.
Conditions
- Allergic Transfusion Reaction
Interventions
PlaceboDrug
The tablet resembles chlorpheniramine but has no therapeutic value.
ChlorpheniramineDrug
An antihistamine that reduces the natural chemical histamine in the body.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The rate of allergic-transfusion reactionsTime frame: within 4 hours from the start of the transfusion
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Hospital
Hefei, Anhui, China · Not yet recruiting
Zhoukou Central Hospital
Zhoukou, Henan, China · Recruiting
The Second Affilated Hospital of Shandong First Medical University
Tai’an, Shandong, China · Recruiting
Regenerative Medicine Center
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.